ClinicalTrials.gg
RecruitingNCT07768007Updated Sep 14, 2026

Real-time Opioid Study

An interventional study of real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback in Substance Use Disorder (SUD), sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Substance-Related Disorders by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · Yale University.

Planned enrollment
54th of 59
3 · median 74
Started
2026
with 2 others
No phase
32 of 63
4 open now
Registered
63rd of 63
by date

Among the 63 studies in Substance-Related Disorders by Yale University, this one is the 54th largest by planned enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2026, is one of 32 with no phase, and was the 63rd registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 63 studies in Substance-Related Disorders by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Substance-Related Disorders by Yale University, or all of them as a file.
02

Study summary

This feasibility study collects initial data on the use of an fMRI neurofeedback protocol for treating anhedonia in methadone-treated individuals with opioid use disorder (OUD). The intervention tested has previously been shown to reduce anhedonia in individuals with depression and this study is collecting first-in-human data in an OUD population. Investigators will assess tolerability of the intervention and collect preliminary data from 2-3 subjects monitoring changes in anhedonia, non-substance-related autobiographical memory recall, and meaning in life.

03

Conditions studied

  • Substance Use Disorder (SUD)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥3 months of methadone treatment for OUD
  • Presence of anhedonia, as assessed via SHAPS
  • Room for improvement in specific autobiographical memory recall, as assessed via AMT

Exclusion criteria

Exclusion Criteria:

  • Failure to pass an MRI screening
  • Women who are pregnant
  • Psychosis, as assessed via Yale PRIME Early Psychosis Screening Test
  • Serious suicidal ideation
  • Serious medical condition
  • Legally blind
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    Individuals with OUD

    Participants will complete five study visits. They will receive neurofeedback at two separate scanning sessions (sessions 2-3). Neurofeedback scans will include rest, neurofeedback, and transfer (i.e., no feedback) runs, one week apart.

    Device: real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback

Interventions

  • Devicereal-time functional magnetic resonance imaging (rt-fMRI) neurofeedback

    A non-invasive, non-pharmacological therapeutic tool that enables an individual to learn to modulate their neural activity in order to effect behavioral change.

06

What researchers measure

Primary outcomes

  1. Number of participants who completed the intervention

    Number of participants who completed the full intervention of those enrolled.

    Time frame: Through study completion, up to one month post second neurofeedback session

  2. Self-report ratings of tolerability

    Questionnaire where participants indicate how worthwhile participating in the study was on a 1-7 Likert scale. Total score range 1-7 with higher numbers indicating greater tolerability.

    Time frame: Up to one month post second neurofeedback session

Secondary outcomes

  1. Percentage of positive memories recalled as assessed by Autobiographical Memory Test (AMT)

    A psychological assessment used to measure how specifically an individual can recall positive personal, life-related events.

    Time frame: Baseline, one week post second neurofeedback session and one month post second neurofeedback session

  2. Changes in anhedonia, as assessed by the Snaith-Hamilton Pleasure Scale (SHAPS)

    Total score range 0-14 with higher scores reflecting a higher level of anhedonia (the inability to experience pleasure).

    Time frame: Baseline, one week post second neurofeedback session and one month post second neurofeedback session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be shared with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2027, 5 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 5 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 17, 2026
StartActual
Sep 8, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07768007
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Sep 8, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Sarah Paprotna
Contact
sarah.paprotna@yale.edu
+1 (203) 737-5994
Michelle Hampson, PhD
principal investigator · Yale University
Kathleen Garrison, PhD
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion